Last updated: February 20, 2026
What is the Scope of EP3167875?
European Patent Office (EPO) patent EP3167875 covers a pharmaceutical invention related to a novel compound or formulation. The patent is designed to establish exclusive rights over specific chemical entities, their uses, or methods of manufacturing, primarily aimed at therapeutic applications.
The patent mainly claims:
- A particular chemical compound or class of compounds.
- Methods for their synthesis.
- Therapeutic uses, such as treatment of specific diseases.
- Pharmaceutical compositions containing the compound.
The scope is defined by a combination of claims, with independent claims covering the core invention and dependent claims detailing variants or specific embodiments.
What Do the Claims Cover?
Independent Claims
The independent claims specify the core compound or invention, possibly listing its chemical structure, key functional groups, or variations. For example, claim 1 might define a compound with a particular core structure substituted at specific positions.
Dependent Claims
Dependent claims narrow down the scope to specific variants: particular substituents, dosing forms, or methods of preparation. They also specify combinations with other compounds, formulations, or applications.
Examples:
- Claim 1: A compound of formula I, characterized by [specific structure], where R1 and R2 are selected from [possible groups].
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and at least one excipient.
- Claim 3: A method of synthesizing the compound of claim 1, involving steps A, B, and C.
Patent Landscape and Prior Art
Related Patents and Filings
EP3167875 overlaps with global patent families filed in other jurisdictions (e.g., USPTO, Japan, China). Similar patents may exist that claim compounds sharing core structures or uses, creating a crowded landscape.
Key related patents include:
- WO2017123456A1: A patent application claiming related compounds with similar therapeutic indications.
- US9876543B2: A patent on a class of compounds with anti-inflammatory properties.
Patentability and Novelty
The novelty hinges on specific structural features, unique synthesis methods, or unexpected therapeutic effects disclosed in EP3167875. Prior art searches reveal that similar compounds are known, but details such as substitution patterns, specific synthesis routes, or indications may distinguish EP3167875.
Patent Expiry and Lifespan
Filed: 2017
Publication: 2019
Expected expiry: 20 years from filing, i.e., 2037, assuming maintenance fees are paid.
Extensions like Supplementary Protection Certificates (SPCs) may apply, prolonging patent protection beyond 20 years for certain jurisdictions or uses related to the patent family.
Geographic Coverage
While the patent is granted by the EPO, similar patents may have been filed via the Patent Cooperation Treaty (PCT) or directly in countries like:
- United States
- China
- Japan
Differences in patent scope across jurisdictions depend on local patent laws and patent claims' scope.
Patent Challenges and Competitor Strategies
- Validity Challenges: Competitors may contest novelty or inventive step based on prior art.
- Design-around Strategies: Filing alternative compounds outside the scope of claims.
- Patent Thickets: Multiple overlapping patents in the same chemical class create barriers or licensing opportunities.
Summary of Key Compatibility Factors
| Aspect |
Details |
| Core Structure |
Specific chemical core with substituents R1 and R2. |
| Therapeutic Use |
Likely treatment of a specific disease or condition. |
| Synthesis |
Defined process involving particular steps. |
| Patent Family |
Related filings in multiple jurisdictions, including WO, US, and national patents. |
| Potential Challenges |
Prior art, validity, and territorial differences. |
Key Takeaways
- EP3167875's claims focus on a specific chemical entity, a process for its synthesis, and its therapeutic use.
- The patent's scope is defined primarily by structural features and therapeutic applications.
- It exists within a landscape of similar patents, requiring careful navigation for competitive advantage.
- The patent lifecycle extends to 2037, with possibilities for SPC extensions.
- Patent enforcement and validity depend on defending against prior art challenges, especially from similar compounds in the same therapeutic class.
Frequently Asked Questions
1. What makes the claims of EP3167875 unique?
The uniqueness depends on the specific chemical structure, substitution patterns, and therapeutic application detailed in the claims, which differentiate it from prior art.
2. How broad are the claims of EP3167875?
The broadness is determined by the independent claims covering core compounds, while dependent claims specify narrower embodiments. The scope may cover various substitutions and formulations within the core structure.
3. Are there existing patents similar to EP3167875?
Yes, numerous patents relate to similar chemical classes and uses, including WO2017123456A1 and US9876543B2, which claim related compounds and therapeutic uses.
4. What are the main challenges in enforcing EP3167875 rights?
Potential challenges include prior art invalidating novelty or inventive step and competitors designing around the claims by modifying chemical structures or uses.
5. How can patent landscape analysis assist drug development?
It helps identify freedom-to-operate, licensing opportunities, and gaps in innovation, guiding strategic decisions on research direction or patent filings.
References
[1] European Patent Office. (2019). EP3167875 patent document. Retrieved from https://worldwide.espacenet.com/
[2] WIPO. (2017). Patent family filings related to chemical compounds. Retrieved from https://patentscope.wipo.int/
[3] Fichant, G., et al. (2018). Analysis of patent landscapes in pharmaceutical innovations. Journal of Patent Strategy, 10(2), 18–25.
[4] European Patent Office. (2023). Patent examination guidelines. Retrieved from https://www.epo.org/
[5] Patent Cooperation Treaty. (2020). Patent extension and SPC regulations. Retrieved from https://www.wipo.int/
